Associate Professor of Internal Medicine
[email protected]
Available to mentor
Patrick W Burke
Clinical Associate Professor
-
Daver NG, Montesinos P, Altman JK, Advani AS, Wang ES, Garciaz S, Martinelli G, Roboz GJ, Walter RB, Begna K, Lunghi M, Platzbecker U, Vyas P, Burke PW, Curti A, DeAngelo DJ, Gastaud L, Schliemann C, Oshrine B, Sallman DA. Journal of Clinical Oncology, 2024 Jun 1; 42 (16_suppl): tps6585 - tps6585.Journal ArticleA phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia.
DOI:10.1200/jco.2024.42.16_suppl.tps6585 -
Foucar CE, Foley DH, Aldous J, Burke PW, Pettit KR, Benitez LL, Perissinotti AJ, Marini BL, Boonstra P, Bixby DL. Eur J Haematol, 2024 Mar; 112 (3): 424 - 432.Journal ArticleReal-world outcomes with immunosuppressive therapy for aplastic anemia in patients treated at the University of Michigan.
DOI:10.1111/ejh.14131 PMID: 37929654 -
Khouderchah CJ, Benitez LL, Marini BL, Fraga M, Pettit K, Burke PW, Bixby DL, Perissinotti AJ. Leuk Lymphoma, 2024 Feb; 65 (2): 228 - 234.Journal ArticleTumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax and hypomethylating agents with or without dose ramp-up.
DOI:10.1080/10428194.2023.2276056 PMID: 37933203 -
Shinn LT, Benitez LL, Perissinotti AJ, Reid JH, Buhlinger KM, van Deventer H, Barth D, Wagner CB, Zacholski K, Desai R, Soule A, Stump SE, Weis TM, Bixby D, Burke P, Pettit K, Marini BL. Int J Hematol, 2023 Dec; 118 (6): 682 - 689.Journal ArticleMulticenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia.
DOI:10.1007/s12185-023-03670-3 PMID: 37882977 -
Daver N, Montesinos P, Altman JK, Wang ES, Martinelli G, Roboz GJ, Begna K, Vyas P, Lunghi M, Platzbecker U, Burke PW, Walter RB, Advani AS, Garciaz S, Gastaud L, Sallman DA, Pemmaraju N, Torres L, Abaza Y, Chan O, Kantarjian HM, Oshrine B, Du Y, Malcolm K, Sweet K. Blood, 2023 Nov 2; 142 (Supplement 1): 2906Journal ArticlePivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia
DOI:10.1182/blood-2023-173413 -
Coe-Eisenberg TD, Perissinotti AJ, Marini BL, Pettit KM, Bixby DL, Burke PW, Benitez L. Ann Hematol, 2023 Nov; 102 (11): 3133 - 3141.Journal ArticleEvaluating the efficacy and toxicity of dose adjusted pegylated L-asparaginase in combination with therapeutic drug monitoring.
DOI:10.1007/s00277-023-05373-5 PMID: 37480389 -
Koenig K, Burgues JMB, Montesinos P, Walker A, Bixby D, Burke P, Daver N, Konopleva M, Anthony S, Tan F, Chen Y, Chen Y, Shen Y, Curran E. HemaSphere, 7 (Suppl): e2546261Journal ArticleP492: SAFETY AND EFFICACY OF LP‐108 AS MONOTHERAPY AND COMBINED WITH AZACITIDINE IN PATIENTS WITH RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR ACUTE MYELOID LEUKEMIA
DOI:10.1097/01.hs9.0000968876.25462.61 -
Daver NG, Montesinos P, Aribi AM, Martinelli G, Wang ES, Altman JK, Roboz GJ, Burke PW, Walter RB, Begna K, Sloss CM, Malcolm KE, Zweidler-McKay PA, Sweet KL. Journal of Clinical Oncology, 2023 Jun 1; 41 (16_suppl): tps7073 - tps7073.Journal ArticleA phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine or magrolimab for patients with CD123-positive acute myeloid leukemia (AML).
DOI:10.1200/jco.2023.41.16_suppl.tps7073
